Data presented here demonstrate that vaccine-induced CD8 þ T cells can eliminate their specific tumor-target with a two-staged attack. First, they release interferon-g that results in growth arrest of the tumor cells via induction of antiangiogenic mediators. Then, during the latter stages of the immune response, CD8 þ effector T cells eradicate the remaining tumor cells through perforinmediated lysis. A combination of these two mechanisms is highly effective in the described model, while either pathway alone fails to completely achieve tumor rejection.
A lthough CD8
þ T cells can prevent spontaneous tumor development, 1 tumor cells commonly circumvent immune surveillance by not providing the type of danger signals required for maturation of dendritic cells into fully competent antigen-presenting cells that are able to stimulate naı¨ve T cells. 2 Vaccines expressing tumorassociated antigens (TAAs) induce immune responses by supplying the needed activation signals to the innate and adaptive immune system, and vaccine-induced TAAspecific CD8 þ T cells have been shown to achieve tumor rejection. 3, 4 The success or failure of immune surveillance against any rapidly proliferating threat is a predicament of numbers versus time. Tumor cells grow very rapidly and can thus hold out against immune surveillance. CD8 þ Tcell-mediated lysis, the ultimate weapon to specifically eliminate transformed cells, is inefficient and time consuming, 5 potentially allowing continued expansion of a tumor even in the presence of a vigorous cytolytic T-cell response. A similar predicament is faced by antiviral CD8 þ T cells that face an even more rapidly multiplying threat. In viral systems, exemplified by a mouse model of hepatitis B virus, CD8 þ T cells can control the infection not only by lysis of virus-infected cells, but also through the release of mediators that reduced production of viral proteins, 6 required for the assembly of infectious virus. Here we demonstrate that vaccine-induced TAAspecific CD8 þ T cells can resort to a similar pathway by eliminating their specific tumor target with a twostaged attack. The model is based on an E1-deleted adenoviral vector expressing the E7 of HPV-16 (termed AdHu5E7) shown previously to induce a potent transgene product-specific CD8 þ T-cell response. 7 AdHu5E7-induced CD8 þ T cells are able to protect mice against challenge with a syngeneic tumor cell line, 4 termed TC-1, expressing the E7 and E6 oncoproteins of human papillomavirus (HPV) type-16. 8 In order to trace the vaccine-induced T cells within regressing tumors, the TC-1 cells were mixed with an extract of growth factor-reduced basement membranes called matrigel, 9 a substance that has been used extensively to study tumor angiogenesis, 10 tumor progression and cancer therapies. 11, 7 Using this model, our data indicate that vaccine-induced E7-specific CD8 þ T cells invade the tumor where they initially release interferon (IFN)-g that affects growth arrest of the tumor cells. This is at least in part achieved through induction of factors, such as MIG, known to inhibit angiogeneisis, 12 which in turn is essential to permit proliferation of transformed cells within a solid tumor. At a later stage, CD8 þ effector T cells eliminate the tumor cells through cytolysis. A combination of these two mechanisms is highly effective in this experimental model, while either pathway alone ultimately fails to inhibit tumor progression.
Results

Vaccine-induced resistance to tumor progression requires IFN-g and perforin
We elucidated how CD8 þ effector-T cells affect tumor regression using a mouse model based on the AdHu5E7 vaccine, which induces CD8 þ T-cell-mediated protection against progression of a transplanted E7-expressing tumor cell line. 4 Genetically engineered mice defective in production of IFN-g (GKO mice) or perforin (PKO mice) were vaccinated with the AdHu5E7 or a control adenoviral vaccine and then challenged s.c. with an E7-expressing epithelial tumor cell line of C57Bl/6 origin. The AdHu5E7 vaccine induced complete resistance to tumor progression in C57Bl/6 mice and provided no protection to GKO mice. AdHu5E7-vaccinated PKO mice were rendered partially resistant. The appearance of tumors was delayed and a fraction of PKO mice remained tumorfree (Fig. 1a) . This suggests that upon vaccination, IFN-g plays an essential role during the initial phase of tumor rejection, while perforin-mediated lysis by the vaccineinduced CD8 þ T cells acts at a later stage. The data also indicate that the early defense provided by IFN-g is absolutely required for vaccine-induced protection against tumor progression, while perforin-mediated lysis facilitates tumor eradication without being indispensable as seen in several experiments where 25-30% of E7-vaccinated PKO mice managed to completely resist tumor progression, while in all experiments E7-immune GKO mice developed tumors. The sequence of CD8 þ T-cell-mediated effector functions was investigated further by adoptive transfer experiments in which PKO mice were transfused several days after tumor cell challenge with splenocytes from AdHuE7-vaccinated GKO or C57Bl/6 mice (Fig. 1b) . Transfer of E7-immune splenocytes from C57Bl/6 mice into shamvaccinated C57Bl/6 mice on the day of tumor cell challenge abrogated tumor progression, while transfer 6 days after tumor cell inoculation had no beneficial effect (Fig. 1c) . Accordingly, sham-vaccinated PKO mice transfused with AdHu5E7-immune GKO splenocytes 6 days after tumor challenge remained susceptible to tumor development. AdHu5E7-immune PKO mice transfused with splenocytes from sham-vaccinated GKO mice (Fig.  1b) showed a similar level of resistance as AdHu5E7-vaccinated PKO mice (Fig. 1a) . Transfer of E7-immune C57Bl/6 or GKO splenocytes, the latter ineffective in their natural hosts, increased resistance to tumor progression in E7-immune PKO mice even when given 6 days after tumor cell challenge (Fig. 1b) . The results demonstrate that tumor eradication in PKO mice can be achieved by late transfusion of E7-specific CD8 þ T cells that have the capacity to eliminate tumor cells through perforinmediated lysis, but are unable to produce IFN-g. Lack of protection in E7-naı¨ve C57Bl/6 mice upon late transfer of E7-immune splenocytes from C57Bl/6 donors shows that in the absence of an earlier immune mechanism that delays tumor progression, destruction of the tumors by CD8 þ T-cell effector mechanisms is no longer attainable.
The kinetics of tumor progression versus tumor infiltration by vaccine-induced CD8 þ T cells
To further differentiate between the kinetics of IFN-g release and perforin-mediated lysis by vaccine-induced 6 TC-1 cells 7 days later. Splenocytes (10 8 /mouse) from AdHu5E7-immune C57Bl/ 6 mice were transfused into naïve C57Bl/6 mice challenged the same day with 10 6 TC-1 cells ('). Splenocytes (10 8 /mouse) from AdHu5E7 (&) or AdHu5L1 ( ) vaccinated C57Bl/6 mice were transferred 7 days after vaccination into C57Bl/6 mice that had been challenged with 10 6 TC-1 cells 6 days earlier.
þ T effector cells, tumor progression was analyzed in relation to tumor infiltration by TAA-specific CD8 þ T cells. Groups of C57Bl/6 mice were vaccinated with the AdHu5E7 vector or an AdHu5 control vector expressing an unrelated antigen. Mice were challenged 1 week later with TC-1 cells or a glioblastoma cell line (GL261) that does not express E7 of HPV-16. Tumor cells were mixed with matrigel to allow for reliable retrieval of small regressing tumors. The tumors were recovered 3 or 6 days later. Infiltrating lymphocytes (TILs) were isolated and frequencies of E7-specific IFN-g-producing CD8 þ T cells were determined by staining for CD8 and intracellular IFN-g (Fig. 2a) . TC-1 tumors recovered from AdHu5E7-vaccinated mice contained E7-specific IFN-g-producing CD8
þ T cells by day 3 after tumor challenge, although absolute numbers were low (o500 E7-specific CD8 þ T cells per tumor). The overall number of CD8 þ T cells and the frequency of E7-specific CD8 þ cells within the tumors increased by day 6. E7-specific IFN-g-producing CD8 þ T cells could not be detected in GL261 tumors (Fig. 2a) 
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Tumor progression was analyzed by limiting dilution upon isolating tumor cells from TC-1 matrigel tumors at different time points after challenge. On day 3, approximately equal numbers of tumor cells were isolated from gels inoculated into AdHu5E7 or sham-vaccinated mice. By day 5, and more pronounced by day 7, the number of tumor cells increased in matrigel tumors from shamvaccinated mice, while numbers gradually declined in E7-immune mice to below 10 4 cells per tumor by day 7 (Fig. 2b) . These results show that vaccine-induced immunity fails to have an instantaneous impact on the number of tumor cells in this model where detectable tumor regression is delayed for at least 3 days.
Vaccine-induced immune mechanisms affect the blood supply of the tumors
To further test for an effect of IFN-g and perforin during the initial critical phase of tumor progression, E7-immune C57Bl/6 mice lacking CD4 þ cells, CD8 þ cells, perforin or IFN-g were challenged with TC-1 cells in matrigel.
Tumors from AdHu5E7-vaccinated mice lacking CD8 þ T cells or IFN-g showed evidence of progression 6 days later (Fig. 2c) . Lack of CD4 þ T cells or perforin did not provide a growth advantage to the tumors during the initial 6 days after challenge, again indicating that perforin-dependent lysis by vaccine-induced CD8 þ T cells has no discernable effect on the early stages of tumor regression.
The recovered matrigel tumors isolated 6 days after challenge from E7-immune C57Bl/6 or PKO mice showed a striking difference in color to those from susceptible mice. Progressing tumors were red while those from resistant mice were pale, potentially due to a deficit in erythrocyte infiltration. Quantitation of the hemoglobin content 10 of the matrigel tumors confirmed that tumors from protected mice contained significantly less hemoglobin compared to those from control mice (Fig. 2d) . The weight of matrigel tumors and their hemoglobin content correlated (correlation coefficient: 0.991) and a similar correlation was seen in an unrelated tumor model based on a transplantable mouse fibrosarcoma cell line (not shown).
To distinguish between lack of angiogenesis and vascular leakage, which would both affect the hemoglobin content, tumors were isolated from AdHu5E7 and shamvaccinated mice 3 days after challenge with TC-1 cells in matrigel. Infiltrating cells were removed and adherent cells were released by enzymatic treatment. The population was screened by microscopy to ensure adequate depletion of lymphoid cells. Adherent cells were stained with a PE-labeled monoclonal antibody to CD31 (PECAM), which is expressed by endothelial cells. We had determined in a series of pre-experiments that TC-1 cells do not express CD31 (data not shown). Cells were analyzed by flow cytometry. Results were gated on live nonlymphoid cells according to forward and side scatter. TC-1 matrigels inoculated into sham-vaccinated mice showed, on day 3, a higher ratio of CD31 þ to CD31
À cells compared to those inoculated into AdHu5E7-immune mice (Fig. 3 ). Results were confirmed by quantitative amplification of transcripts from TC-1 matrigel tumors. Transcripts for the endothelial cell markers tested, that is, CD31 (PECAM), CD36 (scavenger receptor) and CD106 (VCAM), were less abundant in early tumors from AdHu5E7-vaccinated mice than in those from sham-vaccinated animals (ratios of transcript concentration in tumors from sham-vaccinated over E7-immune mice: CD31: 1.7, CD36: 4.5, CD106: 2.5). IFN-g induces production of MIG and IP-10, both known to inhibit angiogenesis. 11-14 IFN-g had been implicated previously to reduce vessel formation within tumors, thus inhibiting progression of IFN-g receptor þ tumor cells. 14, 15 To test for differential gene expression for IFN-g as well as angiogenic (vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF)) and antiangiogenic (IP-10, MIG) factors, transcripts from cells composing the tumor mass were analyzed from 2-, 4-and 6-day-old tumors. Transcripts for MIG, IFN-g, VEGF and bFGF were detectable (Fig. 4a) . Transcripts for IP-10, a downstream mediator of IL-12-induced tumor regression, 16 were too low for reliable detection. Levels of transcripts for MIG, IFN-g, VEGF and bFGF were comparable on day 2 in tumors from vaccinated and sham-vaccinated mice, again indicating a delay for the activity of the vaccine-induced E7-specific immune effectors. By day 4, tumors from E7-immune and E7-naı¨ve mice showed differential transcript expression for all parameters. Transcripts for IFN-g and MIG were two-and four-fold higher in tumors from E7-immune mice, respectively. Transcripts for VEGF were also increased in regressing compared to progressing tumors, while transcripts for bFGF were higher in tumors from E7-naı¨ve compared to E7-immune mice. By day 6, transcript levels for IFN-g, MIG and VEGF declined proportionally in regressing as well as progressing tumors, while levels of bFGF transcripts remained comparable to those on day 4. The results show that the antiangiogenic factor MIG is augmented in tumors from resistant mice CD8 þ T-cell-mediated tumor rejection DW Kowalczyk et al presumably in consequence to the increased levels of IFNg produced by the vaccine-induced E7-specific CD8 þ T cells. IFN-g detected in progressing tumors from shamvaccinated mice as well as some of the IFN-g in the tumors from E7-immune mice may have originated from cells of the innate immune system. The increase in MIG expression correlated with a reduction of bFGF transcripts but did not result in a decrease of VEGF transcripts, which were in contrast augmented in tumors from immune mice. This may in part reflect a reaction of oxygen-deprived cells within the tumors. To determine if transcripts for MIG and VEGF originated from the TILs or the matrigel-adherent cells, the two cell populations were isolated separately from 3-day-old matrigel tumors. Our isolation procedures yielded preparations of TILs that were devoid of detectable contamination with tumor or endothelial cells. However, the matrigel-adherent cell populations contained a low percentage of residual TILs. In E7-immune mice, transcripts for both MIG and more pronounced for VEGF were more abundant in TILs than in matrigel-adherent cells. In tumors from sham-vaccinated mice, transcript levels for VEGF were equally high in both cell populations while levels for MIG were higher (B60%) in TILs (Fig. 4b) . These data implicate the TILs in regressing tumors as the primary source of VEGF and the predominant, albeit not sole, source of MIG.
The vaccine-induced early immune effector mechanisms inhibit tumor cell proliferation
To further corroborate that mediators released by vaccine-induced CD8 þ T cells initially inhibit tumor cell proliferation instead of causing the demise of the tumor cells through perforin or other cytolytic mechanisms, AdHu5E7-and sham-vaccinated mice were challenged with carboxyfluorescein succinimidyl ester (CFSE)-labeled TC-1 cells incorporated into matrigel. CFSE, a fluorescent dye that is retained within the cell, 17 is distributed equally to the daughter cells upon cell division. Consequently, cells become less fluorescent with each division 18 and the degree of loss of fluorescence over time is a reliable measure for cell proliferation. Aliquots of CFSE-labeled TC-1 cells were maintained at logarithmic growth in cell culture. Tumor cells were isolated from tissue culture and from matrigels 2 and 5 days later, and analyzed by flow cytometry. TC-1 cells kept in culture and in sham-vaccinated or E7-immune mice were equally fluorescent on day 2, demonstrating comparable proliferation under either in vitro or in vivo conditions (Fig. 5) . These results confirm, as was indicated by the analysis of tumor cell numbers from day 3 tumors (Fig. 2b) , that vaccine-induced adaptive immune responses had no discernable effect on tumor progression during the initial days after tumor transplantation. By day 5, tumor cells inoculated into mice showed evidence of growth retardation. The mean fluorescence intensity of cells kept in culture declined from B5 Â 10 3 to 2 Â 10 1 log CFSE between days 2 and 5, with the latter being equivalent to the autofluorescence of unlabeled cells exemplified by the left side peak on the day 3 graph. This peak had the same fluorescent intensity as unlabeled TC-1 cells (not shown) and presumably reflects cells derived from the tumorbearing host. TC-1 cells kept in culture thus underwent more than seven cell cycles within 72 hours of logarithmic growth, indicating a doubling time of o10 hours. CFSE- (Fig. 2c) .
Vaccine-induced immune effector mechanisms provide partial protection against bystander tumor cells
The hypothesis that tumor eradication requires initial growth retardation through soluble mediators followed by CD8 þ T-cell-mediated tumor cell lysis, implies that vaccine-induced T cells should retard progression of tumors composed of mixtures of tumor cells, some of which express the antigen that is targeted by the vaccineinduced T cells, while the others lack this antigen. This was tested by vaccinating C57Bl/6 Â BALB/cF1 mice to a MethA tumor cell line that does not express E7 of HPV-
Vaccination with escalating doses of MethA cells provides CD8
þ T-cell-mediated protection against a subsequent challenge with an otherwise fatal dose of MethA tumor cells (not shown). MethA-vaccinated F1 mice remained susceptible to challenge with TC-1 cells (Fig. 6b) . MethA-immune mice also developed tumors upon challenge with a mixture of TC-1 and MethA cells although tumors developed with a slight delay, suggesting temporary growth retardation (Fig. 6b) . MethA-immune F1 mice vaccinated with the AdHu5E7 vaccine 4 days after challenge with the MethA/TC-1 tumor cell mixture were fully protected against tumor development (Fig. 6c) . This was not achieved by AdHu5E7 vaccination of naı¨ve C57Bl/6 mice injected with TC-1 cells given 4 days after challenge (Fig. 6a) , indicating that delayed activation of tumor-specific CD8 þ T cells could only achieve tumor eradication in presence of earlier immune mechanisms, such as cytokines released by MethA-specific CD8 þ T cells that retarded the initial progression of both MethA and TC-1 tumor cells.
Discussion
Data presented here show that TAA-specific CD8 þ T cells wage a two-staged attack on tumor cells. In order to study the CD8 þ T-cell infiltrates in small regressing tumors, the tumor cells were mixed with matrigel prior to their inoculation into mice. Tumor cells mixed at 41C with matrigel, which is liquid at low temperatures but solidifies into a firm gel at body temperature, are retained within the gel upon s.c. injection into mice. They proliferate and through the release of chemokines initiate a lymphocytic infiltrate 7 that can readily be isolated even from regressing tumors that are otherwise difficult to retrieve. Matrigel by itself is neither immunogenic nor elicits an inflammatory reaction in mice.
Our model is based on a potent vaccine that induces frequencies of E7-specific CD8 þ T cells close to 1% of all CD8 þ T cells, which is well in excess to those reported for other efficacious vaccines to E7, such as DNA vaccines. 8 In spite of these high frequencies, less than 10 3 TAAspecific CD8 þ T cells infiltrate the tumor within the first 3 days after tumor challenge. In our model, these 10 3 cytolytic T cells face approximately 10 6 tumor cells. CD8 þ T-cell-mediated cytolysis is inefficient and takes over an hour for each individual T cell-target cell interaction. 5 By day 3 after tumor implantation, the 10 3 infiltrating TAA-specific CD8 þ T cell could thus eliminate less than 10 4 tumor cells by direct lysis during 
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7
) This number of CD8 þ effector T cells can eliminate 10 6 tumor cells within 2-10 hours, but it would not be adequate to cope with the mass of tumor cells that would have meanwhile accumulated without immune-mediated hindrance. Hence, it is crucial for the immune system to rapidly affect growth arrest of tumor cells, which apparently as shown here can be achieved by small numbers of tumor-infiltrating IFN-g-secreting CD8
þ T cells. Putting tumor cell proliferation on halt provides the organism with the time needed for recruitment of additional CD8 þ T effector cells, which can then slowly but irreversibly eliminate individual tumor cells.
In our model, the initial inhibition of tumor cell proliferation requires IFN-g, a multifunctional cytokine that could impair early progression of tumors through a number of pathways. IFN-g has been shown to directly inhibit proliferation of some tumor cells in vitro.
19 TC-1 cells are derived from lung epithelial cells transformed by retroviral vectors expressing oncoproteins (E6 and E7 of HPV-16 and v-Ha-ras) under the control of the Moloney long terminal repeat, a regulatory element that can be modulated by IFN-g, 20 which in turn could effect the cells' growth characteristics. However, proliferation of TC-1 cells was not reduced markedly in vitro in presence of high doses of IFN-g (not shown). In vitro, TC-1 cells upregulate expression of MHC class I determinants in response to IFN-g (not shown) and may become more susceptible to T-cell-mediated cytolysis. This is unlikely to play a major role during the early stages of TC-1 tumor progression in vivo. The kinetics of the delay in tumor progression in PKO mice argues for an interval of several days between the sequential activities of IFN-g and T-cellmediated cytolysis and, furthermore, TC-1 cells, even without pretreatment with IFN-g, are lysed very efficiently by CD8 þ T cells. 7 Our data are most compatible with the notion that IFN-g affected vessel formation through the induction of antiangiogenic mediators such as MIG, which in turn can halt tumor progression by limiting the flow of oxygen and nutrients.
The initial inhibition of tumor cell growth not only provides time for accumulation of vaccine-induced TAAspecific cytolytic T cells but may also have the added benefit to allow for activation of additional cohorts of tumor cell-specific T cells. Monospecific cancer vaccines, especially those directed against proteins that are not essential for the malignant phenotype of a tumor cell, carry the risk that cells with loss mutations of vaccine epitope(s) can evade T-cell-mediated cytolysis. An initial growth retardation may provide an opportunity for presentation of tumor antigens to naı¨ve T cells, thus increasing the repertoire of the tumor-specific CD8 þ T-cell response, which may explain why we consistently observed that a small percentage of AdHu5E7-immune mice were completely protected against challenge with a mixture of E7 þ and E7 À tumor cells (Fig. 6b) .
The concept that mediators released by activated T lymphocytes influence the tumor's supply of nutrients is not novel. Previous studies showed that activated T cells, through the release of factors, promote angiogenesis 21, 22 thus facilitating tumor progression. Notwithstanding, as shown here and by previous studies, 14, 15 T-cell-initiated antiangiogenic pathways can override the angiogenic effect of T-cell-derived factors. This suggests a delicate balance between T-cell-derived mediators that promote or inhibit tumor growth. This has to be acknowledged in the design of active immunotherapy of cancer where poorly efficacious vaccines may harm the patient by promoting rather than inhibiting vessel formation and thus tumor progression as was shown recently with an experimental DNA vaccine to E7. 23 
Material and methods
Mice
Groups (5-10) of female C57Bl/6, perforin knockout (PKO) and IFN-g knockout (GKO) mice purchased from Jackson Laboratory, Bar Harbor, ME, were used at 8-10 weeks of age. 
Vaccines
The AdHu5E7 vaccine and the control adenoviral recombinants have been described in detail previously. 24, 25 Vaccines were given once s.c. at 2 Â 10 7 PFU.
Tumor cell challenge of mice
Tumor cells were either suspended in serum-free medium (L-15) or mixed at a 1:1 ratio with ice-cold matrigel (BD Biosciences, Bedford, MA) before s.c. inoculation into mice. 7 Experiments were conducted two to four times. The data in the result section show tumor progression from one representative experiment.
Antibody depletion
Depletion of T cells and IFN-g was performed as described. 26 Mice were treated with 200 ml of a 1:10 dilution of ascitic fluid containing antibodies GK1.5 (anti-CD4), 5.36.7 (anti-CD8) or XMG1 (anti-IFN-g). Antibodies were injected intraperitoneally on days À4,
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þ T-cell-mediated tumor rejection DW Kowalczyk et al À1, þ 1 and þ 4 relative to tumor injection. To ensure depletion of the T-cell subsets, some of the mice were bled 24 hours after the last injection of antibodies, lymphocytes were isolated, stained with FITC-labeled antibodies to either CD4 or CD8 and analyzed by flow cytometry in parallel to cells from mice that had not been treated with antibodies. Either antibody treatment resulted in 495% depletion of the appropriate T-cell subset in peripheral blood (data not shown).
Isolation of matrigel-infiltrating and -adherent cells
Matrigel tumors were recovered 2-6 days after inoculation into mice. Infiltrating cells were recovered by physical disruption of the gels. Lymphocytes were separated from the gel residues by filtration through a nylon net. The remainder of the gels was washed thoroughly. Tumor cells and endothelial cells were then recovered upon digestion of the gels for 2 hours at 371C with 100 mg/ml of collagenase P followed by trypsinization for 10 min. This procedure resulted in a single cell suspension from which cells were recovered by filtration through a nylon net. Cells were then washed twice in serum-containing medium and analyzed.
Analysis of T-cell frequencies by intracellular cytokine staining
Lymphocytes were analyzed for E7-specific CD8 þ T cells by in vitro culture for 5 hours with peptides carrying the immunodominant epitope of E7 (RAHYNIVTF 27 ) or a peptide carrying an unrelated epitope of p53 (VMCYSPPL 28 ) in presence of Brefeldin, basically as described. 25 Cells were then stained with an FITC-labeled antibody to CD8, permealized and stained with a PElabeled antibody for intracellular IFN-g. After washing, cells were examined by two-color flow cytometry using an EPICS Elite XL (Beckman-Coulter, Inc., Miami, FL) and data were analyzed by WinMDi software.
Analysis of tumor cell frequencies in matrigels isolated from mice
Tumor cells, isolated from matrigels, were quantitated after plating serial log 10 dilutions of cells in 200 ml of complete medium in 96-well flat bottom plates using 4-8 wells for each dilution. Wells showing colonies of growing tumor cells were counted 10-14 days later.
Analysis of endothelial cell frequencies in tumor cellcontaining matrigels isolated from mice Matrigel-adherent cells, isolated by enzymatic digestion of the gels, were analyzed for CD31 (PECAM) by direct immunofluorescence upon staining of 10 6 cells with 25 ml of a 1:100 dilution of a PE-labeled antibody. Stained cells were analyzed by flow cytometry.
Analysis of angiogenesis
Hemoglobin content of matrigel tumors was measured by the Drabkin method. 10 Analysis of tumor cell proliferation TC-1 cells were stained with CFSE (Molecular Probes, Inc., Eugene, OR) for 10 minutes as described, 18 washed and then either plated at 10 4 cells per well in a six-well plate or they were mixed with matrigel and injected into mice. Matrigel tumors were isolated at different days thereafter, infiltrating lymphocytes were removed by thorough washing of gel fragments and tumor cells were recovered upon enzymatic digestion of the gel residues. CFSE-labeled TC-1 cells kept in logarithmic growth in tissue culture as well as unlabeled TC-1 cells were isolated at the same time. Cells were analyzed by flow cytometry for CFSE expression. Results were gated on live cells and expressed as fluorescence intensity of events. To allow for combining several sets of data in one graph, events were normalized.
Analysis of transcript expression
Groups of five mice were injected with TC-1 cells in matrigel. Gels were harvested at different days thereafter and RNA was isolated from homogenized gels. Alternatively, infiltrating lymphocytes were harvested followed by isolation of matrigel-adherent cells. RNA was then recovered from the two separate cell populations. In these experiments, emphasis was given to thoroughly removing as many of the infiltrating lymphocytes from the matrigel prior to enzymatic treatment of the gels. Both the infiltrating-lymphocyte populations and the matrigeladherent cell populations were checked microscopically for crosscontamination. The lymphocyte population typically did not contain any live tumor cells, while matrigeladherent cell populations contained a small number of residual lymphocytes (o10% of all live cells). RNA was isolated separately from the infiltrating lymphocytes and from matrigel-adherent cells. Contaminating DNA was removed by treatment with DNAse. RT-PCR reactions were performed using standard protocols.
Quantitative real-time RT-PCR was performed in a LightCycler with the LightCycler-RNA Amplification Kit SYBR Green I (Roche Diagnostics GmbH, Mannheim, FRG) according to the manufacturer's instructions using 1, 10 and 100 ng of RNA per sample. The assays were standardized by amplification of GAPDH and by the use of a standardization kit (Boehringer Mannheim, GmbH, FRG). Real time RT-PCR included one cycle of reverse transcription at 551C for 10 minutes, followed by 40 cycles of initial denaturation at 951C for 5 seconds, annealing at 551C for 10 seconds, extension at 721C for 18 seconds. The following primers were used: IFN-g, forward primer, CD8 þ T-cell-mediated tumor rejection DW Kowalczyk et al
